Zobrazeno 1 - 10
of 207
pro vyhledávání: '"tenofovir alafenamide fumarate"'
Autor:
Fei Cao, Tao Fan, Xue Jiang, Jian Wang, Yilin Liu, Li Zhu, Ye Xiong, Shaoqiu Zhang, Zhiyi Zhang, Yifan Pan, Yuanyuan Li, Chao Jiang, Juan Xia, Xiaomin Yan, Jie Li, Xingxiang Liu, Chuanwu Zhu, Rui Huang, Chao Wu
Publikováno v:
Virology Journal, Vol 21, Iss 1, Pp 1-10 (2024)
Abstract Background Concerns have been raised regarding changes in lipid profiles among patients with chronic hepatitis B (CHB) during tenofovir alafenamide fumarate (TAF) treatment. We aimed to evaluate the effect of TAF treatment on the lipid profi
Externí odkaz:
https://doaj.org/article/9c30a2c73ee94591a8ff41692cfc79c7
Autor:
Kensuke Abe, Junji Imamura, Akiko Sasaki, Tomoko Suzuki, Satomi Kamio, Taku Obara, Toshihiro Ito
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-12 (2024)
Abstract Background Continued use of tenofovir disoproxil fumarate (TDF), an antiretroviral drug, causes renal function decline and tubular damage in individuals with HIV. While tenofovir alafenamide fumarate (TAF) may have less damaging effects, it
Externí odkaz:
https://doaj.org/article/e17ac65cc36543dab969520cb6dca8d6
Publikováno v:
Infection and Drug Resistance, Vol Volume 16, Pp 3929-3941 (2023)
Jingjing He, Yifei Guo, Yao Zhang, Jiajia Han, Jingwen Chen, Yidi Jia, Zhenxuan Ma, Jingwen Wu, Shenyan Zhang, Fahong Li, Richeng Mao, Jiming Zhang Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emerge
Externí odkaz:
https://doaj.org/article/708a16b322c341f5aa1c6196705c71aa
Publikováno v:
Immunity, Inflammation and Disease, Vol 12, Iss 2, Pp n/a-n/a (2024)
Abstract Objective To compare the efficacy and safety of telbivudine (LdT), tenofovir alafenamide fumarate (TAF), and tenofovir disoproxil fumarate (TDF) for preventing hepatitis B transmission in immune‐tolerant pregnant women with HBV infection.
Externí odkaz:
https://doaj.org/article/ac574d1488a74d239337e80f57b9c69f
Autor:
Giacomo Stroffolini, Valentina Dodaro, Amedeo De Nicolò, Jessica Cusato, Giovanni Di Perri, Antonio D'Avolio, Lucio Boglione
Publikováno v:
Journal of Clinical Virology Plus, Vol 4, Iss 1, Pp 100174- (2024)
Background: Tenofovir disoproxil fumarate (TDF) as first-line therapy for chronic HBV infection is related to nephrotoxicity. Tenofovir alafenamide fumarate (TAF) has been approved with a similar virological and serological response, but lower toxici
Externí odkaz:
https://doaj.org/article/14c0c57ef3724c2a94db2e9a470c149a
Autor:
Ivana Massud, Kenji Nishiura, Susan Ruone, Angela Holder, Chuong Dinh, Jonathan Lipscomb, James Mitchell, George M. Khalil, Walid Heneine, J. Gerardo Garcίa-Lerma, Charles W. Dobard
Publikováno v:
Pharmaceutics, Vol 16, Iss 3, p 384 (2024)
Pre-exposure prophylaxis (PrEP) with a weekly oral regimen of antiretroviral drugs could be a suitable preventative option for individuals who struggle with daily PrEP or prefer not to use long-acting injectables. We assessed in macaques the efficacy
Externí odkaz:
https://doaj.org/article/a522a275318c403b8197fc61f71923cd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-9 (2022)
Key points Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy. Besides, PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment undergoing concurrent TAF prop
Externí odkaz:
https://doaj.org/article/f2cb7053080949dc87d5066299cb2822
Publikováno v:
Pharmaceutical Fronts, Vol 05, Iss 01, Pp e38-e45 (2023)
(R)-Tenofovir phenyl ester ((R)-1) and (R)-tenofovir diphenyl ester ((R)-2) are key intermediates for the practical synthesis of tenofovir alafenamide fumarate, which is a mainstay antiretroviral for the treatment of chronic hepatitis B and HIV-1 inf
Externí odkaz:
https://doaj.org/article/d5643367e63b42ce923b27b0a2f760bd